SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.   )*

                  AFFYMAX INC.                  

(Name of Issuer)

Common Stock

00826A109

December 31, 2007

Check the following box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)
o Rule 13d-1(c)
þ Rule 13d-1(d)

*The remainder of this cover page shall be filled our for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

CUSIP No.		00826A109	13G

*SEE INSTRUCTION BEFORE FILLING OUT !

CUSIP NO. 00826A109	13G

Item 1.		(a).		Name of Issuer:
				Affymax Inc.
		(b).		Address of Issuer’s Principal Executive Offices:
				4001 Miranda Ave.
				Palo Alto, CA 94304
Item 2.		(a).		Names of Person Filing:
				GlaxoSmithKline plc
		(b).		Address of Principal Business Office:
				980 Great West Road
				Brentford
				Middlesex
				TW8 9GS ENGLAND
		(c).		Citizenship:
				England and Wales
		(d).		Title of Class of Securities:
				Common stock.
		(e).		CUSIP Number:
				00826A109
Item 3.				Not Applicable.
Item 4.				Ownership.
				The information in items 1 and 5 through 11 on the cover pages (page 2) on Schedule 13G is hereby incorporated by reference.
Item 5.				Ownership of Five Percent or Less of a Class:

		If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.
Item 6.		Ownership of More Than Five Percent on Behalf of Another Person:
		Shares held by wholly-owned subsidiaries of Reporting Person:

Affymax Technologies N.V.			147,529
Affymax Research Institute			553,236
Glaxo Group Limited			73,764
SmithKline Beecham Corporation			73,764
			848,293

Item 7.		Identification and Classification of Subsidiaries Which
		Acquired the Security Being Reported on by the Parent
		Holding Company:
		Not applicable.
Item 8.		Identification and Classification of Members of the Group:
		Not applicable.
Item 9.		Notice of Dissolution of Group:
		Not applicable
Item 10.		Certification:
		By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

Signature:

After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set
forth in this statement is true, complete and correct.

Dated: February 11, 2008